Champions Oncology(CSBR) - 2025 Q1 - Quarterly Report

Revenue and Income - Oncology services revenue for the three months ended July 31, 2024, was $14.1 million, an increase of 11.9$12.6 million in the same period of 2023[72]. - The company reported a net income of approximately $1.3 million for the three months ended July 31, 2024, with cash provided by operations of approximately$311,000[70]. Costs and Expenses - Cost of oncology services decreased to $7.1 million for the three months ended July 31, 2024, down 8.0$7.7 million in 2023[73]. - Research and development expenses were $1.5 million for the three months ended July 31, 2024, a decrease of 47.9$2.8 million in 2023[74]. - General and administrative expenses decreased to $2.5 million for the three months ended July 31, 2024, down 14.0$2.9 million in 2023[76]. - Total costs and operating expenses for the three months ended July 31, 2024, were $12.7 million, a decrease of 15.8$15.1 million in 2023[71]. Financial Position - As of July 31, 2024, the company had an accumulated deficit of approximately $83.3 million and cash on hand of approximately$2.9 million[70]. - The company may need to raise additional equity or debt capital in the near term to continue funding operations[70]. Research and Development - The company has a pipeline of targets at various stages of discovery and validation, with a select group progressing to therapeutic development[68]. - The company is engaged in developing advanced technology solutions for personalized oncology drug development through its Translational Oncology Solutions[66].